Clinical utility of array comparative genomic hybridisation for prenatal diagnosis: a cohort study of 3171 pregnancies
- 7 February 2012
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 119 (5) , 614-625
Abstract
Please cite this paper as: Lee C, Lin S, Lin C, Shih J, Lin T, Su Y. Clinical utility of array comparative genomic hybridisation for prenatal diagnosis: a cohort study of 3171 pregnancies. BJOG 2012;119:614–625.Objective To evaluate the clinical value of prenatal array comparative genomic hybridisation (CGH) in screening for submicroscopic genomic imbalances.Design Cross‐sectional study.Setting Tertiary referral centre.Population From June 2008 to February 2011, 3171 fetuses underwent prenatal array CGH testing and karyotyping at the National Taiwan University Hospital. Indications for invasive prenatal diagnosis included abnormal karyotype, abnormal ultrasound, advanced maternal age and parental anxiety.Methods In all, 2497 fetuses were screened with 1‐Mb resolution bacterial artificial chromosome array‐based CGH, and 674 fetuses with 60‐K oligonucleotide array‐based CGH. Multiplex ligation‐dependent probe amplification, fluorescence in situ hybridization, or 105‐K oligonucleotide array CGH provided further confirmation.Main outcome measure Copy number variations identified by array CGH.Results Array CGH detected numerical chromosome anomalies in 37 (1.2%) fetuses, microdeletion/duplication in 34 (1.1%) fetuses, large deletion/duplication in 13 (0.4%) fetuses, benign copy number changes in 13 (0.4%) fetuses and variation of unknown clinical significance in five (0.2%) fetuses. Array CGH was effective in identifying submicroscopic genomic imbalance in fetuses with de novo balance translocations (2/17, 1.8%), supernumerary marker chromosomes (3/6, 50%), and abnormal prenatal ultrasound findings (33/194, 17.0%). Array CGH detected microdeletions/duplications in 12 fetuses with normal karyotype.Conclusion Prenatal array CGH is effective in screening for submicroscopic genomic imbalance. Array CGH may add 8.2% to the diagnostic field, compared with conventional karyotyping, for fetuses with abnormal ultrasound results, and is particularly useful in fetuses with karyotypic balanced translocation or marker chromosomes. There is a 0.52% baseline risk of submicroscopic genomic imbalance, even in women with an uneventful prenatal examination.Keywords
This publication has 32 references indexed in Scilit:
- Application of a target array Comparative Genomic Hybridization to prenatal diagnosisBMC Medical Genetics, 2010
- Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital AnomaliesThe American Journal of Human Genetics, 2010
- A retrospective study by oligonucleotide array‐CGH analysis in 50 fetuses with multiple malformationsPrenatal Diagnosis, 2010
- ACOG Committee Opinion No. 446: Array Comparative Genomic Hybridization in Prenatal DiagnosisObstetrics & Gynecology, 2009
- Whole‐genome microarray analysis in prenatal specimens identifies clinically significant chromosome alterations without increase in results of unclear significance compared to targeted microarrayPrenatal Diagnosis, 2009
- Clinical use of array comparative genomic hybridization (aCGH) for prenatal diagnosis in 300 casesPrenatal Diagnosis, 2008
- Comparison of microarray‐based detection rates for cytogenetic abnormalities in prenatal and neonatal specimensPrenatal Diagnosis, 2008
- Diagnostic Genome Profiling in Mental RetardationThe American Journal of Human Genetics, 2005
- Detection of genomic imbalances by array based comparative genomic hybridisation in fetuses with multiple malformationsJournal of Medical Genetics, 2005
- Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic featuresJournal of Medical Genetics, 2004